openPR Logo
Press release

Merck & Co. Ordered to Pay Attorneys’ Fees, Costs Following VIOXX® Consumer Fraud Finding

06-19-2007 01:42 PM CET | Health & Medicine

Press release from: The Lanier Law Firm

ATLANTIC CITY, N.J. – New Jersey Superior Court judge Carol E. Higbee has ordered pharmaceutical giant Merck & Co. to pay fees and costs to a group of attorneys who proved in court that Merck committed fraud by deceiving doctors about the cardiovascular risks of the popular painkiller VIOXX® and deliberately hiding information about those risks from physicians.

Merck could have settled both consumer fraud claims for less than $5,000, but fought the allegations in an April 2006 trial. Similar consumer fraud claims are pending in thousands of additional cases against Merck.

Following the trial, jurors awarded $13.5 million in compensatory and punitive damages to 77-year-old John McDarby, who suffered a heart attack after taking VIOXX® for four years. Jurors also agreed that Merck committed consumer fraud and awarded an additional $4,013.36 to Mr. McDarby and $45 to second victim Thomas Cona based on the cost of their prescriptions.

The order signed June 15 awards approximately $4 million in fees and costs for the attorneys who represented Mr. McDarby and Mr. Cona.

“It is a pity that Merck is forcing our nation’s court system to waste thousands of hours of time and millions of dollars to hear these fraud claims after a jury has already said the company committed fraud,” says lead attorney Mark Lanier of The Lanier Law Firm. “This is lawsuit abuse by Merck, plain and simple.”

The New Jersey Consumer Fraud Act provides for “reasonable attorneys’ fees, filing fees and reasonable costs of suit” to plaintiffs who prove a consumer fraud claim. The New Jersey statute does not limit counsel fees according to the amount of the original claim. According to the court, the law “provides an incentive to competent counsel to undertake high-risk cases and to represent victims of fraud who suffer relatively minor losses.”

The ruling notes that Merck spent $500 million defending Vioxx cases in 2006, and the company has reserved more than $850 million to defend future cases.

Prior to the ruling, Merck withdrew any objection to the amount of time expended by attorneys for the plaintiffs or the hourly rate charged by plaintiffs’ counsel. The company acknowledged in a court filing that Merck’s overall fees and costs “were at least as high as plaintiffs corresponding fees and costs.”

With offices in Houston and New York, The Lanier Law Firm is committed to addressing client concerns with effective and innovative solutions. The firm is composed of outstanding trial attorneys with decades of experience handling cases involving pharmaceutical liability, asbestos exposure, business fraud, serious personal injuries, product liability, and toxic exposure.

The Lanier Law Firm

Houston Law Office
6810 FM 1960 West
Houston, Texas 77069
(713) 659-5200
(713) 659-2204 – Fax

New York Law Office
Lanier Law Firm, PLLC
Tower 56
126 East 56th Street, 6th Floor
New York, NY 10022
(212) 421-2800
(212) 421-2878 – Fax

Press contact:
Alan Bentrup

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Merck & Co. Ordered to Pay Attorneys’ Fees, Costs Following VIOXX® Consumer Fraud Finding here

News-ID: 22495 • Views:

More Releases for Merck

Recombinant Human Interferon Market to Witness Huge Growth by Key Players: Roche …
The Recombinant Human Interferon report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research. The Recombinant Human Interferon research report recognizes and
Nanobodies Market to See Booming Growth 2021-2028 | Novo Nordisk A/S, Merck & Co …
𝐍𝐚𝐧𝐨𝐛𝐨𝐝𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 top level players are analyzed in report based on current and future development status, and Nanobodies market estimations from 2021 to 2028 in terms of revenue and volume. This report provides strategic recommendations consulted by the industrial experts including market share worldwide, future outlook, cost profit structure, supply, raw materials, labour cost, manufacturing expenses, latest market trends, demands, ROI. The Nanobodies market report analyse the manufacturing cost of the
How Epigenomics Market Will Dominate In Coming Years? Key Players: Thermo Fisher …
Fortune Business Insights foresees the pharmaceutical segment to dominate the global epigenomics market on account of the increasing prevalence of chronic diseases such as cancer. According to the World Health Organization (WHO), by the end of 2025, the number of cancer patients will reach 21,471,996. Sample PDF Brochure The increasing prevalence of chronic diseases such as cancer is helping the global epigenomics market to emerge with remarkable market figures, finds
Global Immune Checkpoint Inhibitors Market 2026 : Bristol-Myers Squibb, AstraZen …
Researchmoz added latest report "Global Market Study on Immune Checkpoint Inhibitors: Programmed Death Protein 1 (PD-1) Drug Class to Dominate in Terms of Value Through 2026". The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market. Persistence Market Research (PMR) offers an 8-year forecast on the global immune checkpoint inhibitors market. The primary objective of the report is to offer
Pharmaceuticals Excipients Market 2018 Global Analysis By Key Players – Ashlan …
Summary adds “Pharmaceuticals Excipients Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database. This report provides in depth study of “Pharmaceuticals Excipients Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Pharmaceuticals Excipients Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as
Pneumonia Vaccine Market- GlaxoSmithKline, Pfizer, Merck
Global Pneumonia Vaccine Market Size, Status and Forecast 2022 provides Market information about Manufacturers, Countries, Type and Application.This Industry report also states Company Profile, sales, Pneumonia Vaccine Market revenue and price, market share, market growth and gross margin by regions. Top Manufacturers/Key Players:- GlaxoSmithKline Pfizer Merck Enquiry for buying report @ The Global Pneumonia Vaccine report gives a thorough situation of the present and gauge Pneumonia Vaccine showcase procedures, improvement methodologies and development openings.